Search results for: 'paa1 monitoring software market'

In this research deliverable, Frost & Sullivan’s analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region’s life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transpire ...

08 Oct 2021  |  North America  |  Market Research

Global Tissue Diagnostics (TDx) Growth Opportunities

Companion Diagnostics (CDx)-specific Advanced Staining and Anatomical Pathology Laboratory Information Systems (APLIS) to Drive Ma

Infographics

×

This research service provides an overview of the global TDx market and a 4-year forecast of it from 2021 to 2025. The market will reach $8,848.6 million in 2025, growing at a compound annual growth rate (CAGR) of 8.9% from 2020 to 2025. The advanced staining and anatomical pathology laboratory information management systems (APLIS) segments will g...

03 Oct 2022  |  Global  |  Market Research

Global Prenatal Genetic Testing—Forecast to 2026

Innovation Culture in Screening Drives Prenatal Genetic Testing Growth and Makes it Accessible to More Patients

Infographics

×

New technological advances in prenatal genetic testing include the enhancement of the next-generation sequencing (NGS) technology, chromosomal microarray analysis (CMA) tool, and PCR TaqMan. These improve precision and specificity in genome profiling, augment the efficiency and reliability of testing, and streamline workflow. The study will help...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

27 Jan 2020  |  Global  |  Market Research

Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

Infographics

×

Key Issues Addressed

The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

This research service provides critical insights into the impact of COVID-19 on the global in-vitro diagnostics (IVD) industry, highlighting the growth opportunities, market revenue, and technology trends that influence its growth. Its three major segments identify the strategic imperatives of the IVD industry, the impact of COVID-19 on the IVD gro...

The United States spends more than $3 trillion—nearly 18% of GDP—on healthcare, a massive sector. Healthcare value chain participants face dynamic environments that several trends impact, including the rise in the aging population (16.9% in 2020); chronic disease burden; regulatory challenges; integration across the care continuum; migration to val...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...